Dual release hydrocortisone (plenadren)
Phase 3Small molecule
Dual release hydrocortisone (plenadren) is one of 5 small molecule programs targeting Congenital Adrenal Hyperplasia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Congenital Adrenal Hyperplasia
#DrugCompanyPhaseTrials
1Crenessity
Neurocrine BiosciencesPhase 3
Lu AF95245
LundbeckPhase 2
Atumelnant
CCrinetics Pharmaceuticals Inc.
Phase 3
Dual release hydrocortisone (plenadren)
FFederico II University
Phase 3
Actos
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFederico II University